CN101426766B - 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 - Google Patents
用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 Download PDFInfo
- Publication number
- CN101426766B CN101426766B CN200780014073.4A CN200780014073A CN101426766B CN 101426766 B CN101426766 B CN 101426766B CN 200780014073 A CN200780014073 A CN 200780014073A CN 101426766 B CN101426766 B CN 101426766B
- Authority
- CN
- China
- Prior art keywords
- alkyl
- hydrogen
- unsubstituted
- fluoro
- atom
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c(nc1*)cc(-c2c[n](**c(cc3-c([s]4)nnc4I)nc(*)c3Nc(ccc(I)c3)c3F)nn2)c1Nc(c(F)c1)ccc1I Chemical compound *c(nc1*)cc(-c2c[n](**c(cc3-c([s]4)nnc4I)nc(*)c3Nc(ccc(I)c3)c3F)nn2)c1Nc(c(F)c1)ccc1I 0.000 description 1
- XPAKXMXMJXAIJC-UHFFFAOYSA-N CCS(C)c1c(-c(c(Nc(c(F)c2)ccc2I)cnc2)c2-c(cccc2)c2F)nn[nH]1 Chemical compound CCS(C)c1c(-c(c(Nc(c(F)c2)ccc2I)cnc2)c2-c(cccc2)c2F)nn[nH]1 XPAKXMXMJXAIJC-UHFFFAOYSA-N 0.000 description 1
- YASONZBQQUMWGZ-UHFFFAOYSA-N CN(C)CCNc1nnc(-c(ccnc2)c2Nc(ccc(I)c2)c2F)[o]1 Chemical compound CN(C)CCNc1nnc(-c(ccnc2)c2Nc(ccc(I)c2)c2F)[o]1 YASONZBQQUMWGZ-UHFFFAOYSA-N 0.000 description 1
- LMQSSJJKHKLHKG-UHFFFAOYSA-N COC(c(ccnc1)c1Nc(c(F)c1)ccc1I)=O Chemical compound COC(c(ccnc1)c1Nc(c(F)c1)ccc1I)=O LMQSSJJKHKLHKG-UHFFFAOYSA-N 0.000 description 1
- DPLZFEMPZYQRDT-UHFFFAOYSA-N COc(cc1)cc(F)c1Nc(cncc1)c1-c1nnc(N)[o]1 Chemical compound COc(cc1)cc(F)c1Nc(cncc1)c1-c1nnc(N)[o]1 DPLZFEMPZYQRDT-UHFFFAOYSA-N 0.000 description 1
- ALVOYLJGAPMMLM-UHFFFAOYSA-N N#Cc(c(-c(cccc1)c1F)cnc1)c1Nc(c(F)c1)ccc1I Chemical compound N#Cc(c(-c(cccc1)c1F)cnc1)c1Nc(c(F)c1)ccc1I ALVOYLJGAPMMLM-UHFFFAOYSA-N 0.000 description 1
- ZIRKATSIZNDXJL-UHFFFAOYSA-N NC1=NN=[IH](c(ccnc2)c2Nc(ccc(I)c2)c2F)N1 Chemical compound NC1=NN=[IH](c(ccnc2)c2Nc(ccc(I)c2)c2F)N1 ZIRKATSIZNDXJL-UHFFFAOYSA-N 0.000 description 1
- JYPHUIBJUDAFOA-UHFFFAOYSA-N NNC(c(c(-c(cccc1)c1Cl)cnc1)c1Nc(c(F)c1)ccc1I)=O Chemical compound NNC(c(c(-c(cccc1)c1Cl)cnc1)c1Nc(c(F)c1)ccc1I)=O JYPHUIBJUDAFOA-UHFFFAOYSA-N 0.000 description 1
- CTOOKLLGWHNPED-UHFFFAOYSA-N NNC(c1ccncc1Nc(ccc(I)c1)c1F)=O Chemical compound NNC(c1ccncc1Nc(ccc(I)c1)c1F)=O CTOOKLLGWHNPED-UHFFFAOYSA-N 0.000 description 1
- MJJTXPYNCXUTDO-UHFFFAOYSA-N Nc1nnc(-c(ccnc2)c2Nc(ccc(Br)c2)c2Br)[o]1 Chemical compound Nc1nnc(-c(ccnc2)c2Nc(ccc(Br)c2)c2Br)[o]1 MJJTXPYNCXUTDO-UHFFFAOYSA-N 0.000 description 1
- HHTJBEIYFAHLCN-UHFFFAOYSA-N Nc1nnc(-c(ccnc2)c2Nc(ccc(I)c2)c2F)[o]1 Chemical compound Nc1nnc(-c(ccnc2)c2Nc(ccc(I)c2)c2F)[o]1 HHTJBEIYFAHLCN-UHFFFAOYSA-N 0.000 description 1
- UCVZAMKTVJXRQO-UHFFFAOYSA-N Nc1nnc(-c(ccnc2)c2Nc(ccc(I)c2)c2F)[s]1 Chemical compound Nc1nnc(-c(ccnc2)c2Nc(ccc(I)c2)c2F)[s]1 UCVZAMKTVJXRQO-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210488042.5A CN103121996B (zh) | 2006-04-19 | 2007-04-18 | 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US79307306P | 2006-04-19 | 2006-04-19 | |
| US60/793,073 | 2006-04-19 | ||
| PCT/US2007/009456 WO2007123936A1 (en) | 2006-04-19 | 2007-04-18 | Novel heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210488042.5A Division CN103121996B (zh) | 2006-04-19 | 2007-04-18 | 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101426766A CN101426766A (zh) | 2009-05-06 |
| CN101426766B true CN101426766B (zh) | 2014-03-26 |
Family
ID=38357968
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200780014073.4A Expired - Fee Related CN101426766B (zh) | 2006-04-19 | 2007-04-18 | 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 |
| CN201210488042.5A Expired - Fee Related CN103121996B (zh) | 2006-04-19 | 2007-04-18 | 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210488042.5A Expired - Fee Related CN103121996B (zh) | 2006-04-19 | 2007-04-18 | 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8076486B2 (https=) |
| EP (1) | EP2013180A1 (https=) |
| JP (1) | JP5525812B2 (https=) |
| KR (1) | KR20090005195A (https=) |
| CN (2) | CN101426766B (https=) |
| AR (1) | AR060807A1 (https=) |
| AU (1) | AU2007240860A1 (https=) |
| BR (1) | BRPI0711625A2 (https=) |
| CA (1) | CA2644425A1 (https=) |
| EA (1) | EA200802050A1 (https=) |
| IL (1) | IL194546A0 (https=) |
| MX (1) | MX2008013308A (https=) |
| WO (1) | WO2007123936A1 (https=) |
| ZA (1) | ZA200807263B (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772233B2 (en) * | 2006-04-19 | 2010-08-10 | Merck Serono, S.A. | Arylamino N-heteroaryl compounds as MEK inhibitors |
| CA2707989A1 (en) * | 2007-12-07 | 2009-06-11 | Novartis Ag | Pyrazole derivatives and use thereof as inhibitors of cyclin dependent kinases |
| EP2370568B1 (en) | 2008-12-10 | 2017-07-19 | Dana-Farber Cancer Institute, Inc. | Mek mutations conferring resistance to mek inhibitors |
| EP3028699B1 (en) | 2010-02-25 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Braf mutations conferring resistance to braf inhibitors |
| CN103038364A (zh) | 2010-03-09 | 2013-04-10 | 达纳－法伯癌症研究所公司 | 诊断和治疗具有或发展对于第一种癌症治疗的抗性的患者中的癌症的方法 |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| US20150141470A1 (en) | 2012-05-08 | 2015-05-21 | The Broad Institute, Inc. | Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy |
| WO2014007228A1 (ja) | 2012-07-03 | 2014-01-09 | 小野薬品工業株式会社 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| JP2018507884A (ja) * | 2015-03-10 | 2018-03-22 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | 免疫調節剤としての３−置換１，３，４−オキサジアゾールおよびチアジアゾール化合物 |
| DK3300500T3 (da) | 2015-05-20 | 2020-05-18 | Amgen Inc | Triazolagonister af apj-receptoren |
| US20190008859A1 (en) | 2015-08-21 | 2019-01-10 | Acerta Pharma B.V. | Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor |
| US10150754B2 (en) | 2016-04-19 | 2018-12-11 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| WO2018204532A1 (en) | 2017-05-03 | 2018-11-08 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| CA3073543A1 (en) | 2017-08-21 | 2019-02-28 | Vivace Therapeutics, Inc. | Benzosulfonyl compounds |
| US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
| US11524943B1 (en) | 2017-12-06 | 2022-12-13 | Vivace Therapeutics, Inc. | Benzocarbonyl compounds |
| PL3720438T3 (pl) * | 2017-12-07 | 2024-03-18 | Amplyx Pharmaceuticals, Inc. | Heterocyklicznie podstawione pochodne pirydyny jako środki przeciwgrzybicze |
| CN110317190A (zh) * | 2018-03-28 | 2019-10-11 | 首都医科大学 | 一种三唑-羧酸酯类衍生物在医药领域的应用 |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| EP3793551A4 (en) | 2018-05-16 | 2022-01-26 | Vivace Therapeutics, Inc. | OXADIAZOLE COMPOUNDS |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| EP4054579A1 (en) | 2019-11-08 | 2022-09-14 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| CN115279368B (zh) * | 2019-11-20 | 2024-05-24 | 维瓦斯治疗公司 | 杂芳基化合物 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| EP4346826A4 (en) | 2021-05-27 | 2025-04-30 | Mirati Therapeutics, Inc. | COMBINATION THERAPIES |
| WO2025054260A1 (en) * | 2023-09-07 | 2025-03-13 | Kinnate Biopharma Inc. | Inhibitors of mek kinase |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004056789A1 (en) * | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Mek inhibiting oxa- and thia-diazol-2-yl phenylamine derivates |
| WO2005004818A2 (en) * | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP0105092A3 (en) | 1999-01-13 | 2003-12-29 | Warner Lambert Co | 1-heterocycle substituted diarylamines and medicaments containing them |
| GB2373245A (en) * | 2001-03-12 | 2002-09-18 | Bayer Ag | Pyridinyl pyrazoles and their use for the treatment of COPD |
| AU2003260472A1 (en) | 2002-09-10 | 2004-04-30 | Pharmacia Italia S.P.A. | Substituted pyridine derivatives as antitumor agent |
| WO2004052280A2 (en) * | 2002-12-10 | 2004-06-24 | Imclone Systems Incorporated | Anti-angiogenic compounds and their use in cancer treatment |
| WO2004091480A2 (en) * | 2003-04-09 | 2004-10-28 | Exelixis, Inc. | Tie-2 modulators and methods of use |
| WO2005000818A1 (en) | 2003-06-27 | 2005-01-06 | Warner-Lambert Company Llc | 5-substituted-4-`(substituted phenyl)!amino!-2-pyridone deviatives for use as mek inhibitors |
| CA2546353A1 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
| MX2007004781A (es) * | 2004-10-20 | 2007-05-11 | Applied Research Systems | Derivados de 3-arilamino piridina. |
-
2007
- 2007-04-18 ZA ZA200807263A patent/ZA200807263B/xx unknown
- 2007-04-18 WO PCT/US2007/009456 patent/WO2007123936A1/en not_active Ceased
- 2007-04-18 MX MX2008013308A patent/MX2008013308A/es not_active Application Discontinuation
- 2007-04-18 JP JP2009506558A patent/JP5525812B2/ja not_active Expired - Fee Related
- 2007-04-18 BR BRPI0711625-0A patent/BRPI0711625A2/pt not_active IP Right Cessation
- 2007-04-18 CN CN200780014073.4A patent/CN101426766B/zh not_active Expired - Fee Related
- 2007-04-18 EA EA200802050A patent/EA200802050A1/ru unknown
- 2007-04-18 AU AU2007240860A patent/AU2007240860A1/en not_active Abandoned
- 2007-04-18 CA CA002644425A patent/CA2644425A1/en not_active Abandoned
- 2007-04-18 US US11/788,032 patent/US8076486B2/en not_active Expired - Fee Related
- 2007-04-18 EP EP07755648A patent/EP2013180A1/en not_active Withdrawn
- 2007-04-18 KR KR1020087028187A patent/KR20090005195A/ko not_active Withdrawn
- 2007-04-18 CN CN201210488042.5A patent/CN103121996B/zh not_active Expired - Fee Related
- 2007-04-19 AR ARP070101677A patent/AR060807A1/es unknown
-
2008
- 2008-10-06 IL IL194546A patent/IL194546A0/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004056789A1 (en) * | 2002-12-20 | 2004-07-08 | Warner-Lambert Company Llc | Mek inhibiting oxa- and thia-diazol-2-yl phenylamine derivates |
| WO2005004818A2 (en) * | 2003-07-09 | 2005-01-20 | Imclone Systems Incorporated | Heterocyclic compounds and their use as anticancer agents |
Also Published As
| Publication number | Publication date |
|---|---|
| HK1127354A1 (en) | 2009-09-25 |
| AU2007240860A1 (en) | 2007-11-01 |
| US20070287737A1 (en) | 2007-12-13 |
| ZA200807263B (en) | 2009-11-25 |
| WO2007123936A1 (en) | 2007-11-01 |
| CN103121996A (zh) | 2013-05-29 |
| CA2644425A1 (en) | 2007-11-01 |
| JP5525812B2 (ja) | 2014-06-18 |
| CN103121996B (zh) | 2015-10-21 |
| JP2009534386A (ja) | 2009-09-24 |
| KR20090005195A (ko) | 2009-01-12 |
| US8076486B2 (en) | 2011-12-13 |
| EA200802050A1 (ru) | 2009-04-28 |
| EP2013180A1 (en) | 2009-01-14 |
| IL194546A0 (en) | 2009-08-03 |
| MX2008013308A (es) | 2008-10-27 |
| BRPI0711625A2 (pt) | 2011-12-06 |
| CN101426766A (zh) | 2009-05-06 |
| AR060807A1 (es) | 2008-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101426766B (zh) | 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物 | |
| CN100360507C (zh) | 用取代杂环脲抑制raf激酶 | |
| CN102892759B (zh) | 具有犬尿氨酸产生抑制作用的含氮杂环化合物 | |
| CN100374425C (zh) | 用作放射增敏剂和化疗增敏剂的芳基和杂芳基脲chk1抑制剂 | |
| CN105924437B (zh) | 作为iii型受体酪氨酸激酶抑制剂的化合物 | |
| HK1216887A1 (zh) | 布鲁顿酪氨酸激酶的抑制剂 | |
| WO2023280237A1 (zh) | 一种磷酸酶降解剂的合成和应用 | |
| CN103508961B (zh) | 抗肿瘤药物 | |
| CN107857755A (zh) | 作为trka激酶抑制剂的n‑吡咯烷基、n`‑吡唑基‑脲、硫脲、胍和氰基胍化合物 | |
| CN109890822A (zh) | 细胞代谢过程的抑制剂 | |
| CN105555785B (zh) | 作为dyrk激酶抑制剂的2，3-二氢苯并呋喃-5-基化合物 | |
| CN101868459A (zh) | 用于治疗糖尿病的、作为葡糖激酶激活剂的吡啶-2-基-氨基-1，2，4-噻二唑衍生物 | |
| CN106573906A (zh) | 哌啶‑二酮衍生物 | |
| AU2003242591A1 (en) | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases | |
| CN102971291B (zh) | 新型酰胺衍生物及其作为药物的用途 | |
| CN104109161A (zh) | 2-(2,4,5-取代苯胺)嘧啶衍生物作为egfr调谐子用于治疗癌症 | |
| HK1213544A1 (zh) | 新型二环苯基-吡啶/吡嗪用於治疗癌症 | |
| WO2021136354A1 (zh) | 联苯类衍生物抑制剂、其制备方法和应用 | |
| CN101454313A (zh) | P38抑制剂及其使用方法 | |
| TW200524903A (en) | Quinazoline derivatives | |
| WO2018133826A1 (zh) | 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物 | |
| WO2023202623A1 (zh) | Polq抑制剂化合物及其应用 | |
| CN111356695B (zh) | 新的三环化合物 | |
| WO2018133827A1 (zh) | 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物 | |
| CN112513041B (zh) | 三环化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1127354 Country of ref document: HK |
|
| ASS | Succession or assignment of patent right |
Owner name: MERCK SERONO CO., LTD. Free format text: FORMER OWNER: SERONO LABORATORIES LTD. Effective date: 20100324 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20100324 Address after: Swiss Coyne Hince Applicant after: Merck Serono S.A. Address before: Swiss Coyne Hince Applicant before: LABORATOIRES SERONO S.A. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1127354 Country of ref document: HK |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20140326 |